Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study. [electronic resource]
Producer: 19990303Description: 2377-84 p. digitalISSN:- 1078-0432
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Animals
- Antineoplastic Agents -- administration & dosage
- Cytarabine -- therapeutic use
- Diarrhea -- chemically induced
- Distamycins -- administration & dosage
- Drug Administration Schedule
- Female
- Humans
- Injections, Intravenous
- Leukemia -- drug therapy
- Leukemia, Myeloid, Acute -- drug therapy
- Leukemia, Myelomonocytic, Acute -- drug therapy
- Mice
- Mice, SCID
- Middle Aged
- Nausea -- chemically induced
- Nitrogen Mustard Compounds -- administration & dosage
- Transplantation, Heterologous
- Tumor Cells, Cultured
- Vomiting -- chemically induced
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.